For research use only. Not for use in humans.

Lumretuzumab (Anti-ERBB3 / HER3)

Synonyms: ErbB-3, HER3

Lumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD.

Lumretuzumab (Anti-ERBB3 / HER3)

Quality Control

Batch: A290201 Purity: 99% Protein concentration: 4.45mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR Others
Saracatinib (AZD0530) 312 c-Src,c-YES,LCK
Canertinib (CI-1033) 51
AG-490 132 JAK2 (V617F)
CP-724714 109
WZ4002 34
Sapitinib (AZD8931) 50
CUDC-101 23 HDAC,HDAC1,HDAC6
AG-1478 100
PD153035 HCl 20
Pelitinib (EKB-569) 11 Src,MEK/ERK,Raf
AEE788 (NVP-AEE788) 16 c-Abl,FLT1,c-Fms
AC480 (BMS-599626) 12
AP26113-analog (ALK-IN-1) 5 ALK,IGF1R,INSR
WZ3146 2
Allitinib tosylate 19
Rociletinib (CO-1686) 37
Varlitinib 8
Icotinib (BPI-2009H) 11
TAK-285 5 MEK1,Aurora B,LCK
WHI-P154 11 Src,VEGFR,JAK3
Daphnetin 4 PKA,PKC
PD168393 6
CNX-2006 2
Tyrphostin 9 2 PDGFR
AG-18 1
Icotinib Hydrochloride 0
HS-10296 hydrochloride 3
MTX-531 0 PI3Kα
Avitinib maleate 0 BTK
limertinib 0
AG 825 0 PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 1
AST-1306 10
ErbB2 inhibitor 0
Tuxobertinib (BDTX-189) 3 RIPK2,BLK
Epertinib hydrochloride 1
JND3229 0 EGFR C797S
BI-4020 1
Tyrphostin AG-528 0
AG 556 0
Canertinib dihydrochloride 8
EGFR Inhibitor 4 Microtubules
SU5214 0 VEGFR2
RG 13022 0
TQB3804 1
zipalertinib (TAS6417) 5 TXK,BMX
Pyrotinib dimaleate 6
PD153035 14
AG 494 0
AG 555 1
Theliatinib (HMPL-309) 0
Avitinib (Abivertinib) 3 JAK3,BTK
Lazertinib (YH25448) 9 Del19,L85R
Lifirafenib (BGB-283) 8 WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816) 6
Zorifertinib (AZD3759) 7
CL-387785 (EKI-785) 5
Poziotinib (NOV120101, HM781-36B) 37
AZ5104 6 ACK1,BLK,BRK
AV-412 free base 0
HER2-Inhibitor-1 1
WZ8040 3
Genistein 38 topo II
Rezivertinib 1
BDTX-1535 0
Falnidamol 1
BLU-945 1
(S)-Sunvozertinib ((S)-DZD9008) 1
CH7233163 1
Licochalcone D 1 NF-κB,PARP,Caspase
Furmonertinib Mesylate (AST2818, Alflutinib) 3 CYP3A4
(Rac)-JBJ-04-125-02 0
Tyrphostin AG30 (AG30) 0
AG-1557 0
AG99 0
MTX-211 2 PI3K
RG14620 0 ABCG2
Almonertinib (HS-10296) 4
Cyasterone 1
Norcantharidin 5 c-Met
Naquotinib(ASP8273) 2
EAI045 3
Olmutinib (BI 1482694) 6 BTK
Butein 3
Chrysophanic Acid 3 mTOR
EGCG ((-)-Epigallocatechin Gallate) 42 DNMT,telomerase,FASN
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Lumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD.
References

Product Details

CAS No. 1448327-63-6
Molecular Weight 147.16
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06731907 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug Non-small Cell Lung Cancer Merck Sharp & Dohme LLC 2025-03-30 PHASE2
NCT04165070 RECRUITING Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed Carcinoma, Non-Small-Cell Lung Merck Sharp & Dohme LLC 2019-12-19 PHASE1; PHASE2
NCT05919537 ACTIVE_NOT_RECRUITING Drug: HMBD-001|Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Ge Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor Hummingbird Bioscience 2023-09-06 PHASE1
NCT07701941 NOT_YET_RECRUITING Drug: Patritumab deruxtecan|Drug: Trastuzumab deruxtecan Hormone Receptor Positive; HER2-low or HER2-ultralow; Unresectable or Metastatic Breast Cancer Daiichi Sankyo 2026-08-03 PHASE1; PHASE2
NCT05142189 RECRUITING Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel Non-Small Cell Lung Cancer BioNTech SE 2022-06-17 PHASE1
NCT07193394 RECRUITING Drug: Tucatinib (ONT-380)|Drug: Trastuzumab (Herceptin) Metastatic Breast Cancer ( HER2 Negative); Unresectable Breast Cancer Institut Curie 2026-01-31 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.